CR9567A - Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph - Google Patents

Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph

Info

Publication number
CR9567A
CR9567A CR9567A CR9567A CR9567A CR 9567 A CR9567 A CR 9567A CR 9567 A CR9567 A CR 9567A CR 9567 A CR9567 A CR 9567A CR 9567 A CR9567 A CR 9567A
Authority
CR
Costa Rica
Prior art keywords
formulation
prolonged release
present
active principles
solubility depending
Prior art date
Application number
CR9567A
Other languages
English (en)
Inventor
Alaux Gerard
Andre Frederic
Lewis Gareth
Serre Veronique
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR9567A publication Critical patent/CR9567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invencion se refiere a una formualcion nueva para una liberacion prolongada de un principio activo qu epresenta una solubilidad dependiente del PH. La formulacion de l ainvencion comprende un excipiente matricial a base de polimero hidrofilo que contiene una dosis determinada del principio activo, y tambien comprende uno o varios agentes acidificantes en forma de una sal acida de un acido organico.
CR9567A 2005-06-28 2007-12-06 Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph CR9567A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0506539A FR2887455B1 (fr) 2005-06-28 2005-06-28 Formulation a liberation prolongee de principes actifs de medicaments

Publications (1)

Publication Number Publication Date
CR9567A true CR9567A (es) 2008-02-20

Family

ID=35708770

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9567A CR9567A (es) 2005-06-28 2007-12-06 Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph

Country Status (30)

Country Link
US (1) US20080089936A1 (es)
EP (1) EP1904037A1 (es)
JP (1) JP2008546830A (es)
KR (1) KR101387839B1 (es)
CN (1) CN101217943B (es)
AR (1) AR057410A1 (es)
AU (1) AU2006264856B2 (es)
BR (1) BRPI0612990A2 (es)
CA (1) CA2611125A1 (es)
CR (1) CR9567A (es)
DO (1) DOP2006000144A (es)
EA (1) EA013745B1 (es)
EC (1) ECSP078010A (es)
FR (1) FR2887455B1 (es)
GT (1) GT200600275A (es)
HN (1) HN2006023741A (es)
IL (1) IL187901A0 (es)
MA (1) MA29560B1 (es)
MX (1) MX2007016238A (es)
MY (1) MY150069A (es)
NO (1) NO20080420L (es)
NZ (1) NZ564069A (es)
PA (1) PA8682701A1 (es)
PE (1) PE20070098A1 (es)
TN (1) TNSN07438A1 (es)
TW (1) TWI446934B (es)
UA (1) UA91553C2 (es)
UY (1) UY29637A1 (es)
WO (1) WO2007003746A1 (es)
ZA (1) ZA200711035B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
US20150024042A1 (en) * 2011-09-14 2015-01-22 Pozen Inc. Phased dosing of clopidogrel
IT201700011337A1 (it) * 2017-02-02 2018-08-02 S I I T S R L Servizio Int Imballaggi Termosaldanti Compressa multistrato per la somministrazione di magnesio

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
EP0701815B1 (de) * 1992-01-17 1999-06-30 ALFATEC-PHARMA GmbH Verfahren zur Herstellung von Wirkstoff enthaltenden Pulvern, Granulaten oder Pellets mit einem Gerüst aus hydrophilen Makromolekülen und ihre Verwendung
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU3469100A (en) * 1999-01-05 2000-07-24 Copley Pharmaceutical Inc. Sustained release formulation with reduced moisture sensitivity
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用

Also Published As

Publication number Publication date
ECSP078010A (es) 2008-01-23
UA91553C2 (ru) 2010-08-10
UY29637A1 (es) 2007-01-31
EA013745B1 (ru) 2010-06-30
CA2611125A1 (fr) 2007-01-11
MX2007016238A (es) 2008-03-06
EA200800150A1 (ru) 2008-04-28
US20080089936A1 (en) 2008-04-17
EP1904037A1 (fr) 2008-04-02
NO20080420L (no) 2008-01-22
DOP2006000144A (es) 2007-02-28
ZA200711035B (en) 2009-09-30
KR20080019023A (ko) 2008-02-29
NZ564069A (en) 2012-04-27
WO2007003746A1 (fr) 2007-01-11
CN101217943B (zh) 2012-05-23
JP2008546830A (ja) 2008-12-25
FR2887455B1 (fr) 2007-08-10
HN2006023741A (es) 2011-05-31
AU2006264856A1 (en) 2007-01-11
GT200600275A (es) 2007-03-29
TWI446934B (zh) 2014-08-01
TW200727921A (en) 2007-08-01
IL187901A0 (en) 2008-03-20
KR101387839B1 (ko) 2014-04-22
AR057410A1 (es) 2007-12-05
BRPI0612990A2 (pt) 2011-04-19
MY150069A (en) 2013-11-29
AU2006264856B2 (en) 2011-09-15
PA8682701A1 (es) 2007-01-17
HK1122731A1 (en) 2009-05-29
TNSN07438A1 (en) 2009-03-17
PE20070098A1 (es) 2007-03-01
CN101217943A (zh) 2008-07-09
MA29560B1 (fr) 2008-06-02
FR2887455A1 (fr) 2006-12-29

Similar Documents

Publication Publication Date Title
PE20150998A1 (es) Inhibidores de histona demetilasas
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
CR10404A (es) Composicion farmaceutica de liberacion sostenida sobre la base de un sistema de liberacion que comprende un polimero acido-soluble y un polimero ph-dependiente
AR072842A1 (es) Composicion farmaceutica estabilizada que comprende un ingrediente farmaceuticamente activo no peptidico
GT200600496A (es) Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea.
CL2011000314A1 (es) Composición farmacéutica estable que comprende linaclotida; método de preparación; y uso para preparar un medicamento útil para tratar un desorden gastrointestinal.
NO20034323D0 (no) Medisinske aerosolformuleringer
BRPI0609636A2 (pt) formulações farmacêuticas
AR055838A1 (es) Formulaciones para microproyecciones recubiertas que tienen solubilidad controlada
CO6220902A2 (es) Formulacion en polvo del valganciclovir
ECSP10010588A (es) Formulacion de medicamento solida con liberacion retardada
ECSP11011199A (es) Formulación de depósito de octreotida con niveles de exposición constantemente altos
CR9567A (es) Formulacion de liberacion prolongada de principios activos que presentan una solubilidad dependiente del ph
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
PE20211391A1 (es) Procedimiento para la preparacion de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-acido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmaceutico
AR067048A1 (es) Formulaciones acuosas de acetaminofen para inyeccion.
AR054729A1 (es) Sistema de administracion
BR112015004115A2 (pt) composições farmacêuticas compreendendo flurbiprofeno
ATE530172T1 (de) Pharmazeutische formulierungen mit clopidogrel
ECSP088088A (es) Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas
EP2842938A4 (en) NOVEL BETA-ALANINE DERIVATIVES, PHARMACEUTICALLY SALTS AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE AGENT
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
PE20070012A1 (es) Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil) ftalazin-1-ilo] micronizado, y sus sales
EP4452249A4 (en) PHARMACEUTICAL FORMULATIONS COMPRISING 3-({[(4R)-7-{METHYL[4-(PROPAN-2-YL)PHENYL]AMINO}-3,4-DIHYDRO-2H-L-BENZOPYRAN-4-YL]METHYL}AMINO)PYRIDINE-4-CARBOXYLIC ACID
EA200701741A1 (ru) Композиция, содержащая окаперидон